MedDataX Logo

Nudging Flu Vaccination by Making it Easy for Patients to Schedule a Flu Shot

NCT ID: NCT05493787

Last Updated: 2024-12-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

139503 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-08

Study Completion Date

2023-01-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test whether messages that make it easy to schedule a flu shot appointment will increase flu shot rates in patients without an upcoming appointment. The study will also test which message versions and message timing are most effective for increasing flu vaccination.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The CDC recommends a flu vaccination to everyone aged 6+ months, with rare exception; almost anyone can benefit from the vaccine, which can reduce illnesses, missed work, hospitalizations, and death. Past work from the study team focused on encouraging flu shots for patients with upcoming appointments. However, many patients in the health system do not have any appointments during flu season.

Eligible patients without an upcoming appointment will be randomized to a passive control group (no message), an active control group (a basic message stating that the patient can get a flu shot at Geisinger) or one of several other messages informed by behavioral science ("ease", "waiting for you", "protect yourself - rare outcomes", or "protect yourself - frequent outcomes"). Patients will be randomly assigned to one of several message send dates. Messages sent via patient portal, short message service (SMS) text, email, and/or another modality, will include a link redirecting patients to a page where they can self-schedule a flu shot.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Vaccination Health promotion Health behavior Economics, Behavioral

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Although patients will not be explicitly informed of which arm they were randomized to, they will be aware of the messages they receive.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Passive control

No message

Group Type NO_INTERVENTION

No interventions assigned to this group

Active control message

A message that simply states that patients can get a flu shot at Geisinger

Group Type ACTIVE_COMPARATOR

Reminder

Intervention Type BEHAVIORAL

Patient portal, SMS, email, and/or another modality

Ease message

A message emphasizing the ease of scheduling a flu shot at Geisinger

Group Type EXPERIMENTAL

Reminder

Intervention Type BEHAVIORAL

Patient portal, SMS, email, and/or another modality

Waiting for you message

A message that states the patient's flu shot is "waiting" for them at Geisinger

Group Type EXPERIMENTAL

Reminder

Intervention Type BEHAVIORAL

Patient portal, SMS, email, and/or another modality

Protect yourself - rare message

A message that emphasizes the rare, dangerous outcomes of getting the flu (e.g., hospitalization, pneumonia), and states that a flu shot can offer protection from those outcomes

Group Type EXPERIMENTAL

Reminder

Intervention Type BEHAVIORAL

Patient portal, SMS, email, and/or another modality

Protect yourself - frequent message

A message that emphasizes the outcomes that frequently occur in people with the flu (e.g., fever, chills, missing important events), and states that a flu shot can offer protection from those outcomes

Group Type EXPERIMENTAL

Reminder

Intervention Type BEHAVIORAL

Patient portal, SMS, email, and/or another modality

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Reminder

Patient portal, SMS, email, and/or another modality

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Included in one or both of the following two base patient lists:

1. Geisinger patient portal flu outreach list for Fall 2022
2. A list of patients obtained from Geisinger's Phenomics and Clinical Data Core (PACDC). This list will include active Geisinger patients (all patients on this list attended at least one primary care appointment at Geisinger between 10/1/2008 and 4/13/2022, and either had a Geisinger primary care provider assigned as of April 2022, or were in the Electronic Health Record \[EHR\] since at least September 2021 and had at least one encounter in 2020-2022).
* Aged 18 or older as of October 2022
* Has had a Geisinger encounter in the last 2 years as of October 2022
* Either of the following, as of October 2022:

1. Has a Geisinger PCP assigned in the Community Medicine, Pediatrics, or Internal Medicine service line
2. In the last 2 years, has completed an appointment in a Geisinger specialty on a list of specialties approved by system leadership for flu shot communications
* Has not received a flu-shot during the 2022-23 flu season as of \~1 week prior to the message date (timeline may be slightly different, depending on data pull logistics), according to the Electronic Health Record (EHR)
* Does not have a scheduled in-person primary care or in-person flu-shot-eligible specialty appointment in the 12 weeks following their assigned message send date, as of \~1 week prior to the message date (timelines may be slightly different, depending on data pull logistics or clinical guidance)

* As of this writing, the team plans to define a flu-shot-eligible specialty appointments as appointments in departments that have historically documented or administered flu vaccine. However, this approach may change slightly based on changing clinical guidance.

Exclusion Criteria

* The CMSL/Marketing list will include patients in Geisinger's 65Forward or Community Care populations. If necessary due to logistical constraints, we may exclude these 65Forward and/or Community Care patients from our study.
* Cannot be contacted via the communication modality being used in the study (e.g., patient portal, SMS), e.g., due to insufficient/missing contact information in the EHR or because they opted out
* Has an allergy to flu vaccines according to any EHR allergy table known to the study team
* Has a health maintenance modifier indicating they are permanently discontinued from receiving a seasonal flu shot
* Is on a list of dismissed patients
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Massachusetts Institute of Technology

OTHER

Sponsor Role collaborator

National Bureau of Economic Research, Inc.

OTHER

Sponsor Role collaborator

Geisinger Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Christopher F Chabris, PhD

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christopher F Chabris, PhD

Role: PRINCIPAL_INVESTIGATOR

Geisinger Clinic

Michelle N Meyer, PhD JD

Role: PRINCIPAL_INVESTIGATOR

Geisinger Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Geisinger Clinic

Danville, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-0500

Identifier Type: -

Identifier Source: org_study_id